OxLDL stimulates lipoprotein-associated phospholipase A2 expression in THP-1 monocytes via PI3K and p38 MAPK pathways

Cardiovascular Research

Volumn 85, Issue 4, 2010, Pages 845-852

  Wang, Wen Yi ^a,b   Li, Jie ^a   Yang, Ding ^a   Xu, Wei ^a,b   Zha, Ruo Peng ^a,b   Wang, Yi Ping ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Atherosclerosis; Lp PLA2; OxLDL; P38; PI3K

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; LIPID; LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; OIL; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPID; THROMBOCYTE ACTIVATING FACTOR;

ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; INTROSPECTION; LEUKEMIA CELL; LIPID STORAGE; MACROPHAGE; MONOCYTE; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; STAINING; UPREGULATION;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; 1-PHOSPHATIDYLINOSITOL 3-KINASE; ATHEROSCLEROSIS; CELL LINE; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES; MONOCYTES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 76749145061     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp367     Document Type: Article

References (36)

1. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005;25:923-931. (Pubitemid 40627835)
2. Zalewski A, Macphee C, Nelson JJ. Lipoprotein-associated phospholipase A2: a potential therapeutic target for atherosclerosis. Curr Drug Targets Cardiovasc Hae-matol Disord 2005;5:527-532. (Pubitemid 43008525)
3. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997;272:20963-20966.
4. Tselepis AD, John Chapman M. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl 2002;3:57-68.
5. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet-activating factor acetylhydrolases. J Biol Chem 1997;272:17895-17898.
6. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000;343:1148-1155.
7. Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005;111: 570-575.
8. Winkler K, Winkelmann BR, Scharnagl H, Hoffmann MM, Grawitz AB, Nauck M et al. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation 2005;111:980-987.
9. Gerber Y, McConnell JP, Jaffe AS, Weston SA, Killian JM, Roger VL. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. Arterioscler Thromb Vasc Biol 2006;26:2517-2522. (Pubitemid 44607474)
10. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 2005;26:137-144.
11. MacPhee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydro-lase, generates two bioactive products during the oxidation of low-density lipo-protein: use of a novel inhibitor. Biochem J 1999;338:479-487.
12. Carpenter KL, Dennis IF, Challis IR, Osborn DP, Macphee CH, Leake DS et al. Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages. FEBS Lett 2001;505:357-363.
13. Shi Y, Zhang P, Zhang L, Osman H, Mohler ER 3rd, Macphee C et al. Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis 2007;191:54-62.
14. Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW et al. HDL and the inflammatory response induced by LDL-derived oxidized phospho-lipids. Arterioscler Thromb Vas Biol 2001;21:481-488.
15. Theilmeier G, De Geest B, Van Veldhoven PP, Stengel D, Michiels C, Lox M et al. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE(2/2) mice. FASEB J 2000;14:2032-2039.
16. Hakkinen T, Luoma JS, Hiltunen MO, Macphee CH, Milliner KJ, Patel L et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1999;19:2909-2917.
17. Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26:2523-2529.
18. Lavi S, McConnell JP, Rihal CS, Prasad A, Mathew V, Lerman LO et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 2007;115:2715-2721.
19. Wu X, Zimmerman GA, Prescott SM, Stafforini DM. The p38 MAPK pathway mediates transcriptional activation of the plasma platelet-activating factor acetyl-hydrolase gene in macrophages stimulated with lipopolysaccharide. J Biol Chem 2004;279:36158-36165.
20. Okamoto H, Iwamoto Y, Maki M, Sotani T, Yonemori F, Wakitani K. Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipi-demic animals. Eur J Pharmacol 2003;466:147-154.
21. Blackie JA, Bloomer JC, Brown MJ, Cheng H, Elliott RL, Hammond B et al. The discovery of SB-435495: a potent, orally active inhibitor of lipoprotein-associated phospholipase A2 for evaluation in man. Bioorg Med Chem Lett 2002;12: 2603-2606.
22. Zhang FJ, Cai MJ, Shen JK, Wang YP. Expression and purification of lipoprotein-associated phospholipase A(2), a key enzyme involved in atherosclerosis. Acta Pharmacol Sin 2006;27:679-684.
23. Nonas S, Birukova AA, Fu P, Xing J, Chatchavalvanich S, Bochkov VN et al. Oxidized phospholipids reduce ventilator-induced vascular leak and inflammation in vivo. Crit Care 2008;12:R27.
24. Bochkov VN, Leitinger N. Anti-inflammatory properties of lipid oxidation products. J Mol Med 2003;81:613-626.
25. Henig NR, Aitken ML, Liu MC, Yu AS, Henderson WR Jr. Effect of recombinant human platelet-activating factor-acetylhydrolase on allergen-induced asthmatic responses. Am J Respir Crit Care Med 2000;162:523-527.
26. Opal S, Laterre PF, Abraham E, Francois B, Wittebole X, Lowry S et al. Recombi-nant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med 2004;32:332-341.
27. Wilensky RL, Shi Y, Mohler ER 3rd, Hamamdzic D, Burgert ME, Li J et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008;14:1059-1066.
28. Serruys PW, Garcia-Garcia HM, Buszman P, Erne P, Verheye S, Aschermann M et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor dar-apladib on human coronary atherosclerotic plaque. Circulation 2008;118: 1172-1182.
29. Mohler ER 3rd, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL et al. The effect of darapladib on plasma lipoprotein-associated phos-pholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2008;51:1632-1641.
30. Berliner JA, Subbanagounder G, Leitinger N, Watson AD, Vora D. Evidence for a role of phospholipid oxidation products in atherogenesis. Trends Cardiovasc Med 2001;11:142-147.
31. Leitinger N. Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr Opin Lipidol 2003;14:421-430.
32. Hundal RS, Salh BS, Schrader JW, Gomez-Munoz A, Duronio V, Steinbrecher UP. Oxidized low density lipoprotein inhibits macrophage apoptosis through activation of the PI 3-kinase/PKB pathway. J Lipid Res 2001;42:1483-1491.
33. Utsugi M, Dobashi K, Ono A, Ishizuka T, Matsuzaki S, Hisada T et al. PI3K p110b positively regulates lipopolysaccharide-induced IL-12 production in human macrophages and dendritic cells and JNK1 plays a novel role. J Immunol 2009; 182:5225-5231.
34. Caivano M, Cohen P. Role of mitogen-activated protein kinase cascades in mediating lipopolysaccharide-stimulated induction of cyclooxygenase-2 and IL-1 beta in RAW264 macrophages. J Immunol 2000;164:3018-3025.
35. Chen CC, Wang JK. p38 but not p44/42 mitogen-activated protein kinase is required for nitric oxide synthase induction mediated by lipopolysaccharide in RAW 264.7 macrophages. Mol Pharmacol 1999;55:481-488.
36. Rane MJ, Carrithers SL, Arthur JM, Klein JB, McLeish KR. Formyl peptide receptors are coupled to multiple mitogen-activated protein kinase cascades by distinct signal transduction pathways: role in activation of reduced nicotinamide adenine dinucleotide oxidase. J Immunol 1997;159:5070-5078.